Triple-negative breast cancer: an update on neoadjuvant clinical trials
- PMID: 22461984
- PMCID: PMC3270519
- DOI: 10.1155/2012/385978
Triple-negative breast cancer: an update on neoadjuvant clinical trials
Abstract
Triple-negative breast cancer (TNBC) is an aggressive malignancy with a poor prognosis despite the high rates of response to chemotherapy. This scenario highlights the need to develop novel therapies and/or treatment strategies to reduce the mortality associated with TNBC. The neoadjuvant setting provides a model for rapid assessment of treatment efficacy with smaller patient accruals and over shorter periods of time compared to the traditional adjuvant setting. In addition, a clear surrogate endpoint of improved survival, known as pathologic complete response, already exists in this setting. Here, we review current data from completed and ongoing neoadjuvant clinical trials for TNBC.
Figures
Similar articles
-
Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response.Ann Surg Oncol. 2012 Jan;19(1):253-8. doi: 10.1245/s10434-011-1877-y. Epub 2011 Jul 2. Ann Surg Oncol. 2012. PMID: 21725686 Free PMC article.
-
Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer.J Oncol. 2013;2013:219869. doi: 10.1155/2013/219869. Epub 2013 Aug 1. J Oncol. 2013. PMID: 23983689 Free PMC article.
-
TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy.Ther Adv Med Oncol. 2024 Apr 29;16:17588359241248336. doi: 10.1177/17588359241248336. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38686016 Free PMC article.
-
Evidence reviews for neoadjuvant treatment: Early and locally advanced breast cancer: diagnosis and management: Evidence review J.London: National Institute for Health and Care Excellence (NICE); 2018 Jul. London: National Institute for Health and Care Excellence (NICE); 2018 Jul. PMID: 35072997 Free Books & Documents. Review.
-
Triple negative breast cancer: looking for the missing link between biology and treatments.Oncotarget. 2015 Sep 29;6(29):26560-74. doi: 10.18632/oncotarget.5306. Oncotarget. 2015. PMID: 26387133 Free PMC article. Review.
Cited by
-
Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study.Oncol Res. 2016;23(6):291-302. doi: 10.3727/096504016X14562725373879. Oncol Res. 2016. PMID: 27131315 Free PMC article.
-
The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer.Oncol Rev. 2017 Mar 17;11(1):324. doi: 10.4081/oncol.2017.324. eCollection 2017 Mar 3. Oncol Rev. 2017. PMID: 28382189 Free PMC article. Review.
-
Triterpenoid Saponin AG8 from Ardisia gigantifolia stapf. Induces Triple Negative Breast Cancer Cells Apoptosis through Oxidative Stress Pathway.Oxid Med Cell Longev. 2020 Oct 13;2020:7963212. doi: 10.1155/2020/7963212. eCollection 2020. Oxid Med Cell Longev. 2020. PMID: 33123316 Free PMC article.
-
Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents.Mol Cancer Ther. 2014 Dec;13(12):3175-84. doi: 10.1158/1535-7163.MCT-14-0358. Epub 2014 Sep 24. Mol Cancer Ther. 2014. PMID: 25253784 Free PMC article.
-
A systematic review of datasets that can help elucidate relationships among gene expression, race, and immunohistochemistry-defined subtypes in breast cancer.Cancer Biol Ther. 2021 Sep 2;22(7-9):417-429. doi: 10.1080/15384047.2021.1953902. Epub 2021 Aug 19. Cancer Biol Ther. 2021. PMID: 34412551 Free PMC article.
References
-
- Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. Journal of the American Medical Association. 2006;295(21):2492–2502. - PubMed
-
- Koplin LM, O’Connell TX. A new approach to the management of primary unresectable carcinoma of the breast: is radiation therapy necessary? American Journal of Clinical Oncology. 1983;6(5):599–604. - PubMed
-
- Newman LA. Surgical issues and preoperative systemic therapy. Cancer Treatment and Research. 2008;141:79–98. - PubMed
-
- Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18. Journal of Clinical Oncology. 1998;16(8):2672–2685. - PubMed
-
- Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. Journal of Clinical Oncology. 2008;26(8):1275–1281. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources